Ignite Creation Date:
2024-05-06 @ 3:47 PM
Last Modification Date:
2024-10-26 @ 1:56 PM
Study NCT ID:
NCT04753216
Status:
COMPLETED
Last Update Posted:
2023-01-19
First Post:
2021-02-10
Brief Title:
Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant Recurrent or Refractory Ovarian Fallopian Tube or Primary Peritoneal Cancer
Sponsor:
Organization:
Northwestern University
Study Design
Study Type:
INTERVENTIONAL
Expanded Access Type Individual:
None
Expanded Access Type Intermediate:
None
Expanded Access Type Treatment:
None
Patient Registry:
None
Target Duration:
None
Design Allocation:
Design Intervention Model:
Design Intervention Model Description:
Design Masking Description:
Bio Spec Retention:
None
Bio Spec Description:
None
Enrollment Count:
3
Enrollment Type:
ACTUAL
Design Primary Purpose:
Design Masking:
Phases:
| Name |
|---|
| PHASE2 |
Observational Models:
Time Perspective List:
Who Masked List: